<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096317</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000393439</org_study_id>
    <secondary_id>P30CA013330</secondary_id>
    <secondary_id>AECM-03099</secondary_id>
    <secondary_id>AECM-CA163402</secondary_id>
    <secondary_id>AECM-NMC-03-10-277C</secondary_id>
    <nct_id>NCT00096317</nct_id>
  </id_info>
  <brief_title>Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone In Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as ixabepilone and ketoconazole, work in&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Giving&#xD;
      ixabepilone with ketoconazole may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of giving&#xD;
      ixabepilone together with ketoconazole and to see how well they work in treating patients&#xD;
      with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the effect of ketoconazole on the pharmacokinetics of ixabepilone in patients&#xD;
           with advanced solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety of ixabepilone when administered alone and in combination with&#xD;
           ketoconazole in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of ixabepilone.&#xD;
&#xD;
      During course 1, patients receive oral ketoconazole on days 0-5 and ixabepilone IV over 3&#xD;
      hours on day 1. During course 2 and subsequent courses, patients receive only ixabepilone IV&#xD;
      over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of at least 3 patients receive escalating doses of ixabepilone during course 1 until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that&#xD;
      at which 2 of 3 patients experience dose-limiting toxicity. At least 12 patients are treated&#xD;
      at the MTD.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-35 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2003</start_date>
  <completion_date type="Actual">December 5, 2005</completion_date>
  <primary_completion_date type="Actual">December 5, 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of ketoconazole on the pharmacokinetics of ixabepilone</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of ixabepilone with and without ketoconazole</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
  </secondary_outcome>
  <enrollment type="Actual">29</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumor&#xD;
&#xD;
          -  Unresponsive to currently available therapy OR no known effective treatment exists&#xD;
&#xD;
          -  Measurable or nonmeasurable disease&#xD;
&#xD;
          -  Brain metastases allowed, provided the following criteria are met:&#xD;
&#xD;
               -  Completed cranial radiotherapy at least 4 weeks ago&#xD;
&#xD;
               -  Stable or reduced brain metastases by brain imaging*&#xD;
&#xD;
               -  Clinically stable disease AND no steroid therapy within the past 2 weeks&#xD;
                  (Baseline brain imaging is not required for patients with no signs or symptoms of&#xD;
                  brain metastasis)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens&#xD;
&#xD;
          -  No other concurrent chemotherapy (standard or investigational)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25% of major bone-marrow containing areas (e.g., pelvis or&#xD;
             lumbar spine)&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 1 week since prior minor surgery and recovered&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 weeks since prior drugs that would inhibit or stimulate drug metabolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sridhar Mani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center at Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Goel S, Cohen M, Cömezoglu SN, Perrin L, André F, Jayabalan D, Iacono L, Comprelli A, Ly VT, Zhang D, Xu C, Humphreys WG, McDaid H, Goldberg G, Horwitz SB, Mani S. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008 May 1;14(9):2701-9. doi: 10.1158/1078-0432.CCR-07-4151.</citation>
    <PMID>18451235</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>October 29, 2018</last_update_submitted>
  <last_update_submitted_qc>October 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

